XON - Intrexon Corporation
| Previous Close | 13.74 |
| Open | 13.78 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 900 |
| Day's Range | 13.42 - 14.24 |
| 52 Week Range | 10.26 - 20.67 |
| Volume | 950,597 |
| Avg. Volume | 1,325,206 |
| Market Cap | 1.857B |
| Beta | 1.59 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.04 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.50 |
- CNBC Videos•2 months ago
Cramer's lightning round: Medical device stocks tend to w...
Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.
- GlobeNewswire•3 days ago
Research Report Identifies Acushnet, Capitol Federal Financial, Laredo Petroleum, Intrexon, Corning, and Idera Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet ...
- Motley Fool•7 days ago
Why Intrexon Corporation Stock Is Slipping Today
A regulatory filing delay provides an unpleasant surprise to the biotech's shareholders.
- Zacks•7 days ago
Intrexon Reports Preliminary Earnings and Revenues for Q2
Intrexon (XON) reports preliminary second-quarter 2018 results and expects a loss of 17 cents for the quarter.
- ACCESSWIRE•7 days ago
Today's Research Reports on Trending Tickers: Omeros and Intrexon
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / U.S. markets finished mostly lower on Thursday, as broader market was dragged lower by weak performance from the industrial and energy sector matched with ...
- PR Newswire•7 days ago
Intrexon Business Update and Conference Call
The Company is not announcing final financial results for the quarter ended June 30, 2018 and is delaying the filing of its quarterly report on Form 10-Q. The delay in filing the second quarter report is related to the Company's application of certain aspects of ASC 606 in the Company's first quarter Form 10-Q. The Company will be filing an amended Form 10-Q for the first quarter of 2018. The Company expects to file the second quarter report and amended first quarter report within the next few days. Intrexon and Epimeron, Inc., a world-class provider of gene discovery and biosynthetic pathway optimization, announced the isolation and recombinant expression of a novel gene from the opium poppy (Papaver somniferum) encoding the enzyme thebaine synthase.
- ACCESSWIRE•7 days ago
Intrexon Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Intrexon Corporation (NYSE: XON ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:30 PM Eastern Time. ...
- GlobeNewswire•10 days ago
Ziopharm Oncology Announces Changes to its Board of Directors
Scott Tarriff, a member of the Board since 2015, has been elected to serve as Lead Director, succeeding Sir Murray Brennan, M.D. Both Sir Dr. Brennan and former U.S. Sen. William Wyche Fowler will step down when their terms expire on September 18, 2018, the date of the annual meeting of shareholders. Doug Pagán and Elan Ezickson have been nominated for election to the Board at the Company’s annual meeting of stockholders.
- GlobeNewswire•10 days ago
AquaBounty Technologies, Inc. Results for the quarter and six months ended June 30, 2018
MAYNARD, Mass., Aug. 07, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...
- PR Newswire•14 days ago
Intrexon to Present at the Jefferies 2018 Global Industrials Conference
GERMANTOWN, Md. , Aug. 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...
- PR Newswire•15 days ago
Intrexon to Announce Second Quarter and First Half 2018 Financial Results on August 9th
GERMANTOWN, Md. , Aug. 2, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
- Zacks•16 days ago
What's in Store for Intrexon (XON) This Earnings Season?
Investors are likely to remain focused on Intrexon's (XON) performance along with other developmental updates during second-quarter 2018 earnings call.
- GlobeNewswire•17 days ago
Ziopharm Oncology to Announce Second Quarter 2018 Financial Results, Host Conference Call Aug. 8
The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.
- GlobeNewswire•22 days ago
Ziopharm Oncology Board Responds to Recent Stock Price Decline
Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today responded to the recent stock price decline and announced it expects to add new members to the Company’s Board of Directors and expand its management team. “Over the past year, our Controlled IL-12 and Sleeping Beauty cell therapy platform technologies have progressed, providing a strong scientific foundation for the Company.
Oilprice.com•25 days agoThe Global Cannabis Market Is Set To Explode
2018 saw the North American cannabis market explode, peaking when Canada announced it will fully legalize recreational use, but the opportunities for this commodity are only just beginning
- ACCESSWIRE•last month
Free Technical Research on Intrexon and Three More Biotech Equities
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on XON sign up now at www.wallstequities.com/registration. On Tuesday, July 10, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Tuesday's trading session in bullish territories.
- Bloomberg•last month
Company Lends Stock to Bank. Bank Shorts Stock to Company's CEO. Any Questions?
Intrexon Corp. is a $1.9 billion market-cap biotech company that issued $200 million of convertible bonds last week. The way convertible bonds work is that they are bonds that can be converted into stock: You sell them for $1,000, and at the end of (in this case) five years investors either get a fixed number of shares of stock (if the stock is up more than a certain amount over those five years) or just get their $1,000 back. If short sellers are already selling a lot of a company’s stock short, then there may not be much stock left to borrow.
- Bloomberg•last month
Deutsche Bank Brought in Some Help
Hedge fund managers will decide that they’re better at operating businesses than business operators are, and become activists, and get companies to adopt their operational suggestions. As a private-equity investor, Cerberus often provides advice for a fee to its portfolio companies.
- PR Newswire•2 months ago
Intrexon Announces Pricing of Offerings of Convertible Senior Notes and Common Stock
GERMANTOWN, Md., June 29, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it has priced its offering of $200.0 million aggregate principal amount of its 3.50% Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC"). The Notes will be senior unsecured obligations of the Company and will bear interest at a rate of 3.50% per year, payable semiannually in arrears on January 1 and July 1 of each year, beginning on January 1, 2019. The Notes will mature on July 1, 2023, unless earlier repurchased or converted in accordance with their terms. Prior to April 1, 2023, the Notes will be convertible at the option of the holder only upon the occurrence of certain events and during certain periods. On or after April 1, 2023, the Notes will be convertible at the option of the holder at any time until the business day immediately preceding the maturity date.
- GlobeNewswire•2 months ago
Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
Ziopharm Oncology, Inc. (ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced that it has enrolled the first patient in its Phase 1 clinical trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with recurrent glioblastoma (rGBM). “We are excited about the first-ever dosing of this combination and its potential to bring a potent and controlled anti-tumor immune response to glioblastoma,” said Francois Lebel, M.D., Executive Vice President, Research and Development, Chief Medical Officer at Ziopharm. “By controlling interleukin 12, Ad-RTS-hIL-12 plus veledimex already has shown it can recruit killer T cells into the tumor and increase expression of checkpoints in this microenvironment.
- PR Newswire•2 months ago
Intrexon Announces Proposed Offerings of Convertible Senior Notes and Common Stock
GERMANTOWN, Md., June 27, 2018 /PRNewswire/ -- Intrexon Corporation (XON) (the "Company") today announced that it intends to offer and sell, subject to market and other conditions, $200.0 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in an underwritten offering registered with the Securities and Exchange Commission (the "SEC"). The Company expects to grant the underwriters of the Notes a 30-day option to purchase up to an additional $30.0 million aggregate principal amount of Notes, solely to cover over-allotments, if any. The Notes will be senior unsecured obligations of the Company, and interest will be payable semi-annually in arrears. The Notes will be convertible into cash, shares of the Company's common stock ("Common Stock") or a combination thereof, at the Company's election. The interest rate, conversion rate and other terms of the Notes will be determined upon pricing of the offering of the Notes.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Intrexon
NEW YORK, NY / ACCESSWIRE / June 20, 2018 / U.S. equities slumped on Tuesday as global trade concerns grew after President Trump threatened to impose an additional $400 billion in tariffs on goods from ...
- PR Newswire•2 months ago
Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes
Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.
- PR Newswire•2 months ago
Oxitec to Apply New Generation of Self-limiting Mosquito Technology to Malaria-spreading Mosquitoes
Oxitec, Ltd. ("Oxitec"), a wholly owned subsidiary of Intrexon Corporation (XON) (XON), today announced it is entering into a cooperative agreement with the Bill & Melinda Gates Foundation ("BMGF") to develop a new strain of Oxitec's self-limiting Friendly™ Mosquitoes to combat a mosquito species that spreads malaria in the Western Hemisphere. The parties will build on Oxitec's successful deployment of Friendly™ Aedes mosquitoes to reduce the vector that spreads dengue, Zika and other diseases and apply the self-limiting and male-selecting technology to anopheline vectors that can spread malaria in endemic regions in the Americas, eastern Africa and South Asia.
- CNBC•2 months ago
Cramer's lightning round: Medical device stocks tend to win big
Jim Cramer rattles off his take on callers' favorite stocks, including a group of securities he tends to recommend.
